KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Gains from Investment Securities (2016 - 2025)

West Pharmaceutical Services' Gains from Investment Securities history spans 16 years, with the latest figure at $19.2 million for Q2 2024.

  • For Q2 2024, Gains from Investment Securities fell 11.93% year-over-year to $19.2 million; the TTM value through Jun 2024 reached $17.2 million, up 38.71%, while the annual FY2024 figure was $5.7 million, 14.93% down from the prior year.
  • Gains from Investment Securities for Q2 2024 was $19.2 million at West Pharmaceutical Services, up from $3.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $21.8 million in Q2 2023 and bottomed at -$10.0 million in Q4 2020.
  • The 5-year median for Gains from Investment Securities is -$100000.0 (2021), against an average of $1.7 million.
  • The largest YoY upside for Gains from Investment Securities was 3850.0% in 2022 against a maximum downside of 650.0% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$10.0 million in 2020, then surged by 99.0% to -$100000.0 in 2021, then plummeted by 7400.0% to -$7.5 million in 2022, then rose by 18.67% to -$6.1 million in 2023, then skyrocketed by 414.75% to $19.2 million in 2024.
  • Per Business Quant, the three most recent readings for WST's Gains from Investment Securities are $19.2 million (Q2 2024), $3.7 million (Q1 2024), and -$6.1 million (Q4 2023).